AU2016246738B2 - Anti-Flt-1 antibodies in treating bronchopulmonary dysplasia - Google Patents

Anti-Flt-1 antibodies in treating bronchopulmonary dysplasia Download PDF

Info

Publication number
AU2016246738B2
AU2016246738B2 AU2016246738A AU2016246738A AU2016246738B2 AU 2016246738 B2 AU2016246738 B2 AU 2016246738B2 AU 2016246738 A AU2016246738 A AU 2016246738A AU 2016246738 A AU2016246738 A AU 2016246738A AU 2016246738 B2 AU2016246738 B2 AU 2016246738B2
Authority
AU
Australia
Prior art keywords
antibody
seq
flt
binding fragment
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016246738A
Other languages
English (en)
Other versions
AU2016246738A1 (en
AU2016246738A8 (en
Inventor
Hans De Haard
Dennis KEEFE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2016246738A1 publication Critical patent/AU2016246738A1/en
Publication of AU2016246738A8 publication Critical patent/AU2016246738A8/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: SHIRE HUMAN GENETIC THERAPIES, INC.
Application granted granted Critical
Publication of AU2016246738B2 publication Critical patent/AU2016246738B2/en
Priority to AU2022201781A priority Critical patent/AU2022201781B2/en
Priority to AU2024227035A priority patent/AU2024227035A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016246738A 2015-04-07 2016-04-07 Anti-Flt-1 antibodies in treating bronchopulmonary dysplasia Active AU2016246738B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022201781A AU2022201781B2 (en) 2015-04-07 2022-03-15 Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
AU2024227035A AU2024227035A1 (en) 2015-04-07 2024-10-01 Anti-flt-1 antibodies in treating bronchopulmonary dysplasia

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144247P 2015-04-07 2015-04-07
US62/144,247 2015-04-07
PCT/US2016/026436 WO2016164579A1 (en) 2015-04-07 2016-04-07 Anti-flt-1 antibodies in treating bronchopulmonary dysplasia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022201781A Division AU2022201781B2 (en) 2015-04-07 2022-03-15 Anti-flt-1 antibodies in treating bronchopulmonary dysplasia

Publications (3)

Publication Number Publication Date
AU2016246738A1 AU2016246738A1 (en) 2017-10-26
AU2016246738A8 AU2016246738A8 (en) 2017-12-21
AU2016246738B2 true AU2016246738B2 (en) 2021-12-16

Family

ID=55795198

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016246738A Active AU2016246738B2 (en) 2015-04-07 2016-04-07 Anti-Flt-1 antibodies in treating bronchopulmonary dysplasia
AU2022201781A Active AU2022201781B2 (en) 2015-04-07 2022-03-15 Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
AU2024227035A Pending AU2024227035A1 (en) 2015-04-07 2024-10-01 Anti-flt-1 antibodies in treating bronchopulmonary dysplasia

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022201781A Active AU2022201781B2 (en) 2015-04-07 2022-03-15 Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
AU2024227035A Pending AU2024227035A1 (en) 2015-04-07 2024-10-01 Anti-flt-1 antibodies in treating bronchopulmonary dysplasia

Country Status (10)

Country Link
US (2) US10711065B2 (enrdf_load_stackoverflow)
EP (2) EP4063390A1 (enrdf_load_stackoverflow)
JP (2) JP6797825B2 (enrdf_load_stackoverflow)
CN (1) CN107683143A (enrdf_load_stackoverflow)
AU (3) AU2016246738B2 (enrdf_load_stackoverflow)
CA (1) CA2981961A1 (enrdf_load_stackoverflow)
HK (1) HK1249913A1 (enrdf_load_stackoverflow)
MA (1) MA41900A (enrdf_load_stackoverflow)
MX (1) MX2017012831A (enrdf_load_stackoverflow)
WO (1) WO2016164579A1 (enrdf_load_stackoverflow)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12337027B2 (en) 2018-03-22 2025-06-24 The Children's Medical Center Corporation Methods and compositions relating to lung repair
WO2019246521A1 (en) 2018-06-22 2019-12-26 Shire Human Genetic Therapies, Inc. Anti-flt-1 antibodies in treating bronchopulmonary dysplasia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004008946A2 (en) * 2002-07-19 2004-01-29 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or clamp

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
CN102397542B (zh) 2004-11-18 2014-05-07 英克隆有限责任公司 抗血管内皮生长因子受体-1的抗体
US20060153835A1 (en) * 2005-01-12 2006-07-13 Smith Henry J Treatment of pre-eclampsia in pregnant women using targeted apheresis
US8349325B2 (en) * 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
ES2683953T3 (es) * 2011-02-07 2018-09-28 Aggamin Llc Procedimientos y sistemas para tratar o prevenir trastornos hipertensivos gestacionales
KR102259255B1 (ko) * 2013-01-28 2021-05-31 샤이어 휴먼 지네틱 테라피즈 인크. 뒤시엔느 근위축증의 치료에서의 항-Flt-1 항체
TW201517916A (zh) 2013-03-15 2015-05-16 Lilly Co Eli Ｖｅｇｆｒ１抗體之治療用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004008946A2 (en) * 2002-07-19 2004-01-29 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or clamp

Also Published As

Publication number Publication date
US10711065B2 (en) 2020-07-14
JP2021014473A (ja) 2021-02-12
EP4063390A1 (en) 2022-09-28
MX2017012831A (es) 2018-05-04
AU2016246738A1 (en) 2017-10-26
JP2018517667A (ja) 2018-07-05
US20180100017A1 (en) 2018-04-12
CA2981961A1 (en) 2016-10-13
CN107683143A (zh) 2018-02-09
MA41900A (fr) 2021-06-02
EP3280735A1 (en) 2018-02-14
AU2022201781A1 (en) 2022-04-07
AU2024227035A1 (en) 2024-10-24
AU2022201781B2 (en) 2024-07-18
WO2016164579A1 (en) 2016-10-13
BR112017021416A2 (pt) 2018-07-03
US20210130475A1 (en) 2021-05-06
EP3280735B1 (en) 2022-02-16
JP6797825B2 (ja) 2020-12-09
HK1249913A1 (zh) 2018-11-16
AU2016246738A8 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
AU2024227035A1 (en) Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
US20200362041A1 (en) Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
EP2083863B1 (en) Antibodies to tgf-beta for use in the treatment of infants at risk of developing bronchopulmonary dysplasia
KR20160044045A (ko) 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ)
EP1517703B1 (en) Placental growth factor as a target for the treatment of osteoporosis
JP2022040124A (ja) デュシェンヌ型筋ジストロフィーの治療における抗ｆｌｔ－１抗体
JP2023108031A (ja) 気管支肺異形成症の治療における抗Ｆｌｔ－１抗体
BR112017021416B1 (pt) Uso de um anticorpo anti-flt-1 ou seu fragmento de ligação ao antígeno
CN118021955A (zh) 用于治疗il-17a介导的疾病或病症的方法和组合物

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 31 , NO 42 , PAGE(S) 6143 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME SHIRE HUMAN GENETIC THERAPIES, INC., APPLICATION NO. 2016246738, UNDER INID (54) CORRECT THE TITLE TO READ ANTI-FLT-1 ANTIBODIES IN TREATING BRONCHOPULMONARY DYSPLASIA

PC1 Assignment before grant (sect. 113)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER APPLICANT(S): SHIRE HUMAN GENETIC THERAPIES, INC.

FGA Letters patent sealed or granted (standard patent)